Pharsight

Xtandi patents expiration

XTANDI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7709517 ASTELLAS Diarylhydantoin compounds
Aug, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
May, 2026

(2 years from now)

US8183274 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
Aug, 2026

(2 years from now)

Xtandi is owned by Astellas.

Xtandi contains Enzalutamide.

Xtandi has a total of 3 drug patents out of which 0 drug patents have expired.

Xtandi was authorised for market use on 31 August, 2012.

Xtandi is available in capsule;oral dosage forms.

Xtandi can be used as treatment of patients with castration-resistant prostate cancer (crpc); the treatment of patients with metastatic castration-sensitive prostate cancer, the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc).

The generics of Xtandi are possible to be released after 13 August, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 16, 2022

Drugs and Companies using ENZALUTAMIDE ingredient

Market Authorisation Date: 31 August, 2012

Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; Treatment of patients with castration-resistant prostate cancer (crpc)

Dosage: CAPSULE;ORAL

How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage

XTANDI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic